Navigation Links
Gene therapy study shows safety and statistically significant improvement in Parkinson's disease

Neurologix, Inc. (OTC Bulletin Board: NRGX) today announced the publication in the June 23 issue of the journal The Lancet of positive results from the first ever gene therapy trial for Parkinson’s disease and the first report of direct gene transfer into a patient’s own brain cells for any adult neurodegenerative disease.

The open label Phase 1 study, conducted in 12 patients with advanced Parkinson’s disease demonstrated both a lack of adverse events related to the gene therapy procedure and statistically significant improvements from baseline in both clinical symptoms and abnormal brain metabolism (as measured by positron emission tomography, or PET scanning). Although all patients had symptoms on both sides of the body, the procedure was performed on only one side of the brain, enabling the untreated side to serve as a study control. The reported improvements were observed primarily on the treated side of the body beginning three months after the gene therapy procedure and persisted through the 12 months formal study period.

Neurologix sponsored the study as part of its ongoing efforts to develop this and other gene therapy approaches to the treatment of neurodegenerative and metabolic diseases. Principal investigators Michael G. Kaplitt, MD, PhD, and Matthew J. During, MD, PhD, performed the procedures at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. Andrew Feigin, MD and David Eidelberg, MD of the Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System performed the clinical evaluations and the PET scans. Neurologix scientists were also co-investigators in the study.

“This ground-breaking study represents not only an encouraging first step in the development of a promising new approach to Parkinson’s disease therapy, but also provides a platform to translate a variety of new gene therapy agents into human clinical trials for many devastating brain disorders,” said Paul Greengard, PhD,
'"/>

Source:JKureczka@comcast.net


Page: 1 2 3 4

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... expression, but what happens if preventative measures are not used? ... of their way not to be HIV tested, increasing the ... et al. in AIDS journal discussed how mother-to-child ... a short course of antiretroviral therapy. However, this is effective ...
... discovery of unusual liver proteins, found only in males, that ... B virus (HBV) sexually discriminates -- hitting men harder than ... Journal of Proteome Research , a monthly publication. ... B seems to progress and cause liver damage faster in ...
... a distant fourth in terms of carbon dioxide ... but its rapid economic growth rate coupled with ... consequences if "business as usual" continues. That,s why ... been working to expand collaborations with India on ...
Cached Biology News:Berkeley Lab lends expertise to India to promote energy efficiency 2Berkeley Lab lends expertise to India to promote energy efficiency 3Berkeley Lab lends expertise to India to promote energy efficiency 4Berkeley Lab lends expertise to India to promote energy efficiency 5
(Date:12/15/2014)... , Dec. 15, 2014  GlassesOff Inc. (OTCBB: GLSO) ... as an independent director of the Company,s Board ... AeroScout and served as its CEO until its acquisition ... a $240 million transaction. Recognized as the inventor of ... leadership, AeroScout provided Wi-Fi -based RFID solutions focused on ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
(Date:12/13/2014)... and Virgin Unite Canada, the non-profit foundation of the Virgin ... Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... Centre to announce the new partnership, which includes the development ... $1 million in seed capital provided by Virgin Unite Canada ... Foundation, founded by Alison Lawton . ...
(Date:12/13/2014)... The DNA Microarray market market was valued at ... grow at a CAGR of 15.2% from 2014 ... the DNA Microarray for an in-depth analysis of ... various tables and figures. , http://www.micromarketmonitor.com/market-report/dna-microarray-reports-5177428198.html ... instrument, consumables, and services, where the consumables market ...
Breaking Biology Technology:AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4
... 2011 Leading events organiser UBM Live and ... announced details of the anticipated content and new developments taking ... International pharmaceutical event, being held from 18-20 April, 2011 at ... of events surrounding CPhI Japan includes P-MEC Japan, which covers ...
... PARK, Md., March 8, 2011 -- The Maryland Technology ... semifinalists for the University of Maryland $75K Business ... competition has served as a launch pad for ... among 71 entries in the categories of high-technology and ...
... Surgical Technology today announces the market launch of their ... in extremities and pelvis. The new ... of Foot and Ankle Surgeons (ACFAS) convention in Fort ... Legato™, will be included. Legato is a resorbable, collagen-based ...
Cached Biology Technology:UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 2UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 3UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 4Mtech Announces Semifinalists for University of Maryland $75K Business Plan Competition 2Mtech Announces Semifinalists for University of Maryland $75K Business Plan Competition 3Mtech Announces Semifinalists for University of Maryland $75K Business Plan Competition 4Mtech Announces Semifinalists for University of Maryland $75K Business Plan Competition 5Mtech Announces Semifinalists for University of Maryland $75K Business Plan Competition 6Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities and Pelvis Market 2
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
CD45/CD34 combination 50 tests...
XPC Immunogen: XPC (NP_004619, 141 a.a. ~ 251 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
Biology Products: